 PLANO, Texas--BUSINESS WIRE--- RETA--Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, or we, a clinical-stage biopharmaceutical company, today announced that it has completed its pre-New Drug Application NDA meeting with the United States Food and Drug Administration FDA for omaveloxolone for the treatment of patients with Friedreichs ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022. The purpose of the pre-NDA meeting was to discuss the conte 